Janus Henderson Investors US’s Insys Therapeutics, Inc. INSY Stock Holding History

Janus Henderson Investors US’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,754,828	Closed	-$28.1M	–	1220
2016 Q1	$28.1M	Sell	1,754,828 -1,201,234	-41%	-$22.8M	0.02%	523
2015 Q4	$84.6M	Sell	2,956,062 -731,321	-20%	-$20.3M	0.07%	312
2015 Q3	$105M	Buy	3,687,383 +263,678	+8%	+$9.7M	0.09%	270
2015 Q2	$123M	Buy	3,423,705 +204,901	+6%	+$6.38M	0.1%	270
2015 Q1	$93.6M	Sell	3,218,804 -442,994	-12%	-$11.7M	0.08%	323
2014 Q4	$77.2M	Buy	3,661,798 +570,532	+18%	+$11.3M	0.07%	359
2014 Q3	$59.9M	Buy	3,091,266 +638,058	+26%	+$10M	0.05%	381
2014 Q2	$38.3M	Buy	2,453,208 +1,550,234	+172%	+$25.1M	0.04%	465
2014 Q1	$18.7M	Buy	902,974 +224,455	+33%	+$4.45M	0.02%	566
2013 Q4	$8.76M	Buy	+678,519	New	+$9.41M	0.01%	690

Other funds holding INSY

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FHAM

Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Janus Henderson Investors US's INSY Position: Q2 2016 in Review

Janus Henderson Investors US sold out of Insys Therapeutics, Inc. (INSY) in Q2 2016, closing a stake of 1,754,828 shares — an estimated $28.1M sold.

Janus Henderson Investors US first reported a position in INSY in Q4 2013 and held it in 10 quarters. The position peaked at $123M in Q2 2015. 124 funds tracked by Wall St. Rank hold INSY as of Q2 2016.

Janus Henderson Investors US reported no remaining Insys Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
Janus Henderson Investors US sold 1,754,828 Insys Therapeutics, Inc. shares in Q2 2016, an estimated $28.1M.
Janus Henderson Investors US first reported a position in Insys Therapeutics, Inc. in Q4 2013 and held it in 10 quarters.
Janus Henderson Investors US's Insys Therapeutics, Inc. position peaked at $123M in Q2 2015.
124 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2016.

Based on Janus Henderson Investors US's 13F filing for Q2 2016, filed 12 Aug 2016.